Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 23;7(2):106–113. doi: 10.1016/j.ncrna.2022.01.002

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Fig. 1 — A general view of transcriptome profiles of the in vitro and biopsy samples. (A) The cluster tree of the in vitro samples' transcriptome profiles. (B) The cluster tree of the biopsy samples' transcriptome profiles. The biopsy samples included heart failure patients without a cancer history (Control) and heart failure patients who underwent cancer treatment with ANT (LateCardiotoxicity_with_ANT) and without ANT (LateCardiotoxicity). The ending numbers are patient IDs (C) The gene type of expressed genes (the average read count across samples >0, annotated using the Ensembl database) in the in vitro samples. (D) Gene types of overlapped differentially expressed genes (545 genes) across all in vitro ANT-treated conditions compared to control samples. (E) The number of differentially expressed genes in each in vitro ANT-treated condition compared to control samples. P-adj <0.01. Con_DF2: control samples; DOX: doxorubicin, EPI: epirubicin, IDA: idarubicin; The: therapeutic dose, Tox: toxic dose; 002, 008, 024, 072, 168, 240, 336 are corresponding exposure periods; ANT: anthracycline(s).